SLC1A5 and cancer: Given that MYC, SLC1A5, and mTORC1 levels are higher in glutamine-addicted cancer cells, along with glutaminase levels, all of these can be exploited in future clinical studies as biomarkers to identify patients when assessing the potential effectiveness of glutaminolysis inhibitors.